Filing Flows › Health Care › Onconetix (ONCO)
Onconetix (ONCO) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Onconetix (ONCO) Q2 2026 earnings results →
Q2 2026 Revenue down 84% year over year to $17K
Onconetix made $17K in Q2 2026 (-84% Y/Y). Operating margin n/m, net loss $2.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $17K in Q2 2026, down 84% year over year and down 20% from the previous quarter.
Gross margin was 25.1%, down 41.1 points from Q2 2025. Operating costs exceeded revenue by $2.7M, an operating margin of -15950.9%. Operating expenses grew 36% against a revenue fall of 84%. The fastest-growing cost line was SG&A (+47%). The quarter ended with a net loss of $2.9M, narrower than the previous quarter's $4.2M loss.
Operating cash flow was −$1.9M. Non-cash charges added back $3K of depreciation and amortization and $7K of share-based compensation. Working capital and other items added $939K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $17K | -84% | n/m | −$2.9M | −$1.9M |
| Q1 2026 | 10-Q | May 13, 2026 | $21K | -79% | n/m | −$4.2M | −$2.1M |
| Q4 2025 | 10-K | Mar 13, 2026 | $304K | -57% | -422.1% | $5.7M | −$3.1M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $304K | -25% | -681.5% | −$8.8M | −$3.2M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $106K | -85% | n/m | −$2.4M | −$1.4M |
| Q1 2025 | 10-Q | Jun 12, 2025 | $102K | -86% | n/m | −$8.5M | −$2.0M |
| Q4 2024 | 10-K | Jun 2, 2025 | $712K | — | n/m | −$29.4M | −$918K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About Onconetix
We are a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology. Through our acquisition of Proteomedix, which closed on December 15, 2023, we own Proclarix, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the In Vitro Diagnostic Regulation (“IVDR”), which we anticipate will be marketed in the U.S. as a lab developed test through our license agreement with LabCorp.
In its own words, from its 10-K, filed Mar 13, 2026.
Onconetix against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -84% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ONCO Onconetix | Q2 2026 | $17K | -84% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Onconetix 10-Q on SEC EDGAR · CIK 1782107 · Pharmaceutical Preparations
13F: who owns ONCO and who is buying
More on ONCO
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results